Tags

Type your tag names separated by a space and hit enter

Serum galectin-9 as a noninvasive biomarker for the detection of endometriosis and pelvic pain or infertility-related gynecologic disorders.
Fertil Steril. 2017 12; 108(6):1016-1025.e2.FS

Abstract

OBJECTIVE

To investigate the usefulness of soluble galectin-9 (Gal-9) in the noninvasive laboratory diagnosis of endometriosis and various gynecologic disorders.

DESIGN

Prospective case-control study.

SETTING

University medical centers.

PATIENT(S)

A total of 135 women of reproductive age were involved in the study, 77 endometriosis patients, 28 gynecologic controls, and 30 healthy women.

INTERVENTION(S)

Diagnostic laparoscopy and collection of tissue biopsies, peritoneal cells, and native peripheral blood from different case groups of gynecology patients and healthy women.

MAIN OUTCOME MEASURE(S)

The expression of mRNA and serum concentration of Gal-9.

RESULT(S)

Semiquantitative reverse transcription-polymerase chain reaction analysis and serum soluble Gal-9 ELISA were performed on three different cohorts of patients: those with endometriosis, those with benign gynecologic disorders, and healthy controls. Differences in the Gal-9 concentrations between the investigated groups and the stability of Gal-9 in the serum and diagnostic characteristics of Gal-9 ELISA were determined by statistical evaluation and receiver operating characteristic (ROC) curve analysis. Significantly elevated Gal-9 levels were found in both minimal-mild (I-II) and moderate-severe (III-IV) stages of endometriosis in comparison with healthy controls. At a cutoff of 132 pg/mL, ROC analysis revealed an excellent diagnostic value of Gal-9 ELISA in endometriosis (area under the curve = 0.973) with a sensitivity of 94% and specificity of 93.75%, indicating better diagnostic potential than that of other endometriosis biomarkers. Furthermore, various pelvic pain or infertility-associated benign gynecologic conditions were also associated with increased serum Gal-9 levels.

CONCLUSION(S)

Our results suggest that Gal-9 could be a promising noninvasive biomarker of endometriosis and a predictor of various infertility or pelvic pain-related gynecologic disorders.

Authors+Show Affiliations

First Department of Obstetrics and Gynaecology, Semmelweis University, Budapest, Hungary.First Department of Obstetrics and Gynaecology, Semmelweis University, Budapest, Hungary.First Department of Obstetrics and Gynaecology, Semmelweis University, Budapest, Hungary.Department of Medical Microbiology and Immunology, University of Pecs, Pecs, Hungary; Janos Szentagothai Research Centre, Pecs, Hungary.Department of Medical Microbiology and Immunology, University of Pecs, Pecs, Hungary; Janos Szentagothai Research Centre, Pecs, Hungary.Department of Medical Microbiology and Immunology, University of Pecs, Pecs, Hungary; Janos Szentagothai Research Centre, Pecs, Hungary.First Department of Obstetrics and Gynaecology, Semmelweis University, Budapest, Hungary.Department of Medical Microbiology and Immunology, University of Pecs, Pecs, Hungary; Janos Szentagothai Research Centre, Pecs, Hungary. Electronic address: polgar.beata@pte.hu.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

29202955

Citation

Brubel, Reka, et al. "Serum Galectin-9 as a Noninvasive Biomarker for the Detection of Endometriosis and Pelvic Pain or Infertility-related Gynecologic Disorders." Fertility and Sterility, vol. 108, no. 6, 2017, pp. 1016-1025.e2.
Brubel R, Bokor A, Pohl A, et al. Serum galectin-9 as a noninvasive biomarker for the detection of endometriosis and pelvic pain or infertility-related gynecologic disorders. Fertil Steril. 2017;108(6):1016-1025.e2.
Brubel, R., Bokor, A., Pohl, A., Schilli, G. K., Szereday, L., Bacher-Szamuel, R., Rigo, J., & Polgar, B. (2017). Serum galectin-9 as a noninvasive biomarker for the detection of endometriosis and pelvic pain or infertility-related gynecologic disorders. Fertility and Sterility, 108(6), 1016-e2. https://doi.org/10.1016/j.fertnstert.2017.09.008
Brubel R, et al. Serum Galectin-9 as a Noninvasive Biomarker for the Detection of Endometriosis and Pelvic Pain or Infertility-related Gynecologic Disorders. Fertil Steril. 2017;108(6):1016-1025.e2. PubMed PMID: 29202955.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serum galectin-9 as a noninvasive biomarker for the detection of endometriosis and pelvic pain or infertility-related gynecologic disorders. AU - Brubel,Reka, AU - Bokor,Attila, AU - Pohl,Akos, AU - Schilli,Gabriella Krisztina, AU - Szereday,Laszlo, AU - Bacher-Szamuel,Reka, AU - Rigo,Janos,Jr AU - Polgar,Beata, PY - 2017/05/04/received PY - 2017/09/05/revised PY - 2017/09/06/accepted PY - 2017/12/6/entrez PY - 2017/12/6/pubmed PY - 2017/12/16/medline KW - ELISA KW - Endometriosis KW - biomarker KW - galectin-9 KW - serum SP - 1016 EP - 1025.e2 JF - Fertility and sterility JO - Fertil. Steril. VL - 108 IS - 6 N2 - OBJECTIVE: To investigate the usefulness of soluble galectin-9 (Gal-9) in the noninvasive laboratory diagnosis of endometriosis and various gynecologic disorders. DESIGN: Prospective case-control study. SETTING: University medical centers. PATIENT(S): A total of 135 women of reproductive age were involved in the study, 77 endometriosis patients, 28 gynecologic controls, and 30 healthy women. INTERVENTION(S): Diagnostic laparoscopy and collection of tissue biopsies, peritoneal cells, and native peripheral blood from different case groups of gynecology patients and healthy women. MAIN OUTCOME MEASURE(S): The expression of mRNA and serum concentration of Gal-9. RESULT(S): Semiquantitative reverse transcription-polymerase chain reaction analysis and serum soluble Gal-9 ELISA were performed on three different cohorts of patients: those with endometriosis, those with benign gynecologic disorders, and healthy controls. Differences in the Gal-9 concentrations between the investigated groups and the stability of Gal-9 in the serum and diagnostic characteristics of Gal-9 ELISA were determined by statistical evaluation and receiver operating characteristic (ROC) curve analysis. Significantly elevated Gal-9 levels were found in both minimal-mild (I-II) and moderate-severe (III-IV) stages of endometriosis in comparison with healthy controls. At a cutoff of 132 pg/mL, ROC analysis revealed an excellent diagnostic value of Gal-9 ELISA in endometriosis (area under the curve = 0.973) with a sensitivity of 94% and specificity of 93.75%, indicating better diagnostic potential than that of other endometriosis biomarkers. Furthermore, various pelvic pain or infertility-associated benign gynecologic conditions were also associated with increased serum Gal-9 levels. CONCLUSION(S): Our results suggest that Gal-9 could be a promising noninvasive biomarker of endometriosis and a predictor of various infertility or pelvic pain-related gynecologic disorders. SN - 1556-5653 UR - https://www.unboundmedicine.com/medline/citation/29202955/Serum_galectin_9_as_a_noninvasive_biomarker_for_the_detection_of_endometriosis_and_pelvic_pain_or_infertility_related_gynecologic_disorders_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0015-0282(17)31912-X DB - PRIME DP - Unbound Medicine ER -